Vivos Cost Of Revenue vs Revenue Per Share Analysis

VVOS Stock

USD 5.18 0.85 19.63%

Vivos Therapeutics financial indicator trend analysis is much more than just breaking down Vivos Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Vivos Therapeutics is a good investment. Please check the relationship between Vivos Therapeutics Cost Of Revenue and its Revenue Per Share accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vivos Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Vivos Stock please use our How to Invest in Vivos Therapeutics guide.

Cost Of Revenue vs Revenue Per Share

Cost Of Revenue vs Revenue Per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Vivos Therapeutics Cost Of Revenue account and Revenue Per Share. At this time, the significance of the direction appears to have very week relationship.

The correlation between Vivos Therapeutics' Cost Of Revenue and Revenue Per Share is 0.2. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Revenue Per Share in the same time period over historical financial statements of Vivos Therapeutics, assuming nothing else is changed. The correlation between historical values of Vivos Therapeutics' Cost Of Revenue and Revenue Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Vivos Therapeutics are associated (or correlated) with its Revenue Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Revenue Per Share has no effect on the direction of Cost Of Revenue i.e., Vivos Therapeutics' Cost Of Revenue and Revenue Per Share go up and down completely randomly.

Correlation Coefficient

0.2

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Cost Of Revenue

Cost of Revenue is found on Vivos Therapeutics income statement and represents the costs associated with goods and services Vivos Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Revenue Per Share

The amount of revenue generated by a company per share of stock, calculated by dividing total revenue by the average number of shares outstanding.

Most indicators from Vivos Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Vivos Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vivos Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Vivos Stock please use our How to Invest in Vivos Therapeutics guide.At this time, Vivos Therapeutics' Selling General Administrative is comparatively stable compared to the past year. Issuance Of Capital Stock is likely to gain to about 13.2 M in 2025, whereas Enterprise Value Multiple is likely to drop (1.67) in 2025.

	2022	2024	2025 (projected)
Interest Expense	1.2M	1.4M	1.4M
Depreciation And Amortization	669K	581K	535.3K

Interest Expense Depreciation And Amortization

Vivos Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity
Total Assets		0.24	0.84	0.61	0.92	0.59	0.68	0.3	0.56	-0.97	-0.46	0.28	0.99	0.01	0.46	0.49	-0.62	0.99	0.79	-0.62	0.7	0.29	-0.24	-0.73	0.86	0.6
Short Long Term Debt Total	0.24		0.52	0.88	-0.13	0.53	0.38	0.46	0.81	-0.02	-0.54	0.71	0.17	0.3	0.74	0.77	-0.76	0.17	0.16	-0.79	0.44	0.29	0.39	0.24	0.57	0.48
Other Current Liab	0.84	0.52		0.86	0.6	0.69	0.76	0.48	0.78	-0.74	-0.66	0.67	0.81	0.19	0.7	0.74	-0.81	0.81	0.57	-0.83	0.81	0.34	0.13	-0.38	0.88	0.73
Total Current Liabilities	0.61	0.88	0.86		0.27	0.67	0.62	0.5	0.92	-0.44	-0.66	0.76	0.56	0.23	0.86	0.89	-0.89	0.56	0.44	-0.92	0.69	0.34	0.26	-0.06	0.82	0.66
Total Stockholder Equity	0.92	-0.13	0.6	0.27		0.34	0.48	0.06	0.25	-0.97	-0.19	-0.07	0.94	-0.16	0.19	0.2	-0.3	0.94	0.8	-0.29	0.47	0.15	-0.48	-0.85	0.65	0.36
Other Liab	0.59	0.53	0.69	0.67	0.34		0.96	0.91	0.46	-0.39	-0.97	0.8	0.47	0.78	0.24	0.39	-0.87	0.47	0.03	-0.82	0.87	0.74	0.59	-0.36	0.75	0.96
Net Tangible Assets	0.68	0.38	0.76	0.62	0.48	0.96		0.85	0.44	-0.52	-0.94	0.73	0.58	0.7	0.25	0.39	-0.83	0.58	0.11	-0.79	0.91	0.7	0.5	-0.42	0.8	0.96
Property Plant And Equipment Net	0.3	0.46	0.48	0.5	0.06	0.91	0.85		0.35	-0.09	-0.92	0.84	0.16	0.94	0.06	0.16	-0.7	0.16	-0.29	-0.63	0.79	0.57	0.81	-0.2	0.57	0.91
Current Deferred Revenue	0.56	0.81	0.78	0.92	0.25	0.46	0.44	0.35		-0.42	-0.43	0.63	0.52	0.09	0.87	0.82	-0.7	0.52	0.5	-0.75	0.55	0.01	0.09	-0.04	0.81	0.47
Net Debt	-0.97	-0.02	-0.74	-0.44	-0.97	-0.39	-0.52	-0.09	-0.42		0.26	-0.06	-0.99	0.18	-0.38	-0.38	0.43	-0.99	-0.85	0.43	-0.57	-0.14	0.43	0.77	-0.73	-0.43
Retained Earnings	-0.46	-0.54	-0.66	-0.66	-0.19	-0.97	-0.94	-0.92	-0.43	0.26		-0.84	-0.35	-0.8	-0.28	-0.43	0.89	-0.35	0.1	0.84	-0.87	-0.79	-0.71	0.16	-0.67	-0.96
Accounts Payable	0.28	0.71	0.67	0.76	-0.07	0.8	0.73	0.84	0.63	-0.06	-0.84		0.17	0.73	0.42	0.49	-0.78	0.17	-0.15	-0.76	0.71	0.42	0.79	0.01	0.57	0.8
Cash	0.99	0.17	0.81	0.56	0.94	0.47	0.58	0.16	0.52	-0.99	-0.35	0.17		-0.12	0.47	0.49	-0.54	1.0	0.86	-0.55	0.62	0.22	-0.36	-0.72	0.8	0.49
Non Current Assets Total	0.01	0.3	0.19	0.23	-0.16	0.78	0.7	0.94	0.09	0.18	-0.8	0.73	-0.12		-0.22	-0.1	-0.48	-0.12	-0.56	-0.4	0.56	0.54	0.88	-0.08	0.29	0.74
Non Currrent Assets Other	0.46	0.74	0.7	0.86	0.19	0.24	0.25	0.06	0.87	-0.38	-0.28	0.42	0.47	-0.22		0.97	-0.66	0.47	0.57	-0.73	0.43	0.11	-0.07	0.2	0.63	0.29
Other Assets	0.49	0.77	0.74	0.89	0.2	0.39	0.39	0.16	0.82	-0.38	-0.43	0.49	0.49	-0.1	0.97		-0.78	0.49	0.5	-0.84	0.51	0.33	0.04	0.2	0.66	0.4
Long Term Debt	-0.62	-0.76	-0.81	-0.89	-0.3	-0.87	-0.83	-0.7	-0.7	0.43	0.89	-0.78	-0.54	-0.48	-0.66	-0.78		-0.54	-0.26	0.99	-0.85	-0.7	-0.44	0.1	-0.82	-0.86
Cash And Short Term Investments	0.99	0.17	0.81	0.56	0.94	0.47	0.58	0.16	0.52	-0.99	-0.35	0.17	1.0	-0.12	0.47	0.49	-0.54		0.86	-0.55	0.62	0.22	-0.36	-0.72	0.8	0.49
Net Receivables	0.79	0.16	0.57	0.44	0.8	0.03	0.11	-0.29	0.5	-0.85	0.1	-0.15	0.86	-0.56	0.57	0.5	-0.26	0.86		-0.31	0.22	-0.14	-0.7	-0.53	0.57	0.05
Good Will	-0.62	-0.79	-0.83	-0.92	-0.29	-0.82	-0.79	-0.63	-0.75	0.43	0.84	-0.76	-0.55	-0.4	-0.73	-0.84	0.99	-0.55	-0.31		-0.81	-0.66	-0.39	0.05	-0.82	-0.81
Common Stock Total Equity	0.7	0.44	0.81	0.69	0.47	0.87	0.91	0.79	0.55	-0.57	-0.87	0.71	0.62	0.56	0.43	0.51	-0.85	0.62	0.22	-0.81		0.57	0.45	-0.35	0.82	0.96
Common Stock Shares Outstanding	0.29	0.29	0.34	0.34	0.15	0.74	0.7	0.57	0.01	-0.14	-0.79	0.42	0.22	0.54	0.11	0.33	-0.7	0.22	-0.14	-0.66	0.57		0.47	0.0	0.36	0.67
Non Current Liabilities Total	-0.24	0.39	0.13	0.26	-0.48	0.59	0.5	0.81	0.09	0.43	-0.71	0.79	-0.36	0.88	-0.07	0.04	-0.44	-0.36	-0.7	-0.39	0.45	0.47		0.29	0.07	0.61
Inventory	-0.73	0.24	-0.38	-0.06	-0.85	-0.36	-0.42	-0.2	-0.04	0.77	0.16	0.01	-0.72	-0.08	0.2	0.2	0.1	-0.72	-0.53	0.05	-0.35	0.0	0.29		-0.45	-0.34
Other Current Assets	0.86	0.57	0.88	0.82	0.65	0.75	0.8	0.57	0.81	-0.73	-0.67	0.57	0.8	0.29	0.63	0.66	-0.82	0.8	0.57	-0.82	0.82	0.36	0.07	-0.45		0.76
Other Stockholder Equity	0.6	0.48	0.73	0.66	0.36	0.96	0.96	0.91	0.47	-0.43	-0.96	0.8	0.49	0.74	0.29	0.4	-0.86	0.49	0.05	-0.81	0.96	0.67	0.61	-0.34	0.76

Click cells to compare fundamentals

Vivos Therapeutics Account Relationship Matchups

Vivos Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	25.3M	33.7M	13.7M	10.7M	15.3M	18.0M
Short Long Term Debt Total	1.3M	1.6M	2.4M	2.0M	1.5M	2.1M
Other Current Liab	3.2M	2.9M	1.6M	2.5M	1.5M	2.2M
Total Current Liabilities	7.8M	7.5M	6.8M	7.3M	5.0M	7.2M
Total Stockholder Equity	16.9M	25.5M	4.8M	411K	8.0M	9.0M
Property Plant And Equipment Net	871.6K	2.8M	4.8M	4.7M	4.4M	3.1M
Current Deferred Revenue	2.9M	2.4M	2.9M	2.1M	896K	1.7M
Net Debt	(16.9M)	(22.4M)	(1.1M)	352K	(4.7M)	(5.0M)
Retained Earnings	(35.3M)	(55.6M)	(79.5M)	(93.1M)	(104.2M)	(99.0M)
Accounts Payable	781K	920K	1.4M	2.1M	1.1M	1.2M
Cash	18.2M	24.0M	3.5M	1.6M	6.3M	8.7M
Non Current Assets Total	4.9M	6.4M	8.3M	8.3M	7.8M	7.5M
Non Currrent Assets Other	1.1M	356K	374K	307K	216K	396.3K
Cash And Short Term Investments	18.2M	24.0M	3.5M	1.6M	6.3M	8.7M
Net Receivables	1.5M	1.7M	457K	202K	430K	671.4K
Common Stock Shares Outstanding	728.4K	849.3K	920.5K	1.2M	5.0M	5.3M
Liabilities And Stockholders Equity	25.3M	33.7M	13.7M	10.7M	15.3M	18.0M
Non Current Liabilities Total	587.1K	641K	2.1M	3.0M	2.4M	1.8M
Other Current Assets	1.3M	1.6M	1.4M	616K	783K	1.0M
Other Stockholder Equity	50.8M	81.2M	84.3M	93.5M	112.1M	72.2M
Total Liab	8.4M	8.2M	8.9M	10.3M	7.3M	9.0M
Net Invested Capital	18.2M	26.8M	4.8M	411K	8.0M	7.4M
Property Plant And Equipment Gross	871.6K	4.1M	6.5M	7.0M	7.2M	4.4M
Total Current Assets	20.4M	27.3M	5.4M	2.5M	7.5M	10.5M
Net Working Capital	12.6M	19.8M	(1.4M)	(4.8M)	2.5M	2.4M
Short Term Debt	867.0K	1.3M	838K	474K	954K	952.9K
Intangible Assets	270.1K	341K	302K	420K	370K	403.7K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Vivos Stock Analysis

When running Vivos Therapeutics' price analysis, check to measure Vivos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivos Therapeutics is operating at the current time. Most of Vivos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivos Therapeutics' price. Additionally, you may evaluate how the addition of Vivos Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC